Thread by @MonicaGandhi9

Slides from ACIP meeting in progress on increased risk of myocarditis/pericarditis in 2nd dose mainly in young males, now seen down to 12 years: can't tell what recommendation they will make on pause/warning, 1 dose, etc. but slides here
cdc.gov/vaccines/acip/…

Higher than expected after 2nd dose in 12-29 year olds

Symptoms (484 cases): Chest pain, shortness of breath, EKG changes, elevated troponins (marker of myocardial damage), abnormal echocardiograms (ultrasound of heart) - proportions below (number over 484 to get %)

Still adjudicating of the 484 cases - of the 323 adjudicated, 309 hospitalized although majority of did well in short-term, will need to not do vigorous exercise usually for 3 months. ACIP/CDC/FDA will make recommendation today on this.

Given this data on delta variant from this am PHE, could consider 1 dose for males ages 12-3 or delaying 2nd dose for a while (8-12 weeks): Vaccine effectiveness against hospitalization with delta similar to that seen with alpha - 94% after 1st dose, 96% after 2nd dose Pfizer

Also, if you are 18 and older and male, you can get the J&J vaccine which has not been associated with this side effect. So, the decision ACIP should make is for the 12-17 year old children on these findings (reduce dose, 1 dose, space out doses, pause/warning, etc.)

Here is source of article above
media.tghn.org/articles/Effec…